# Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

## TL;DR

This study finds that cytoreductive nephrectomy improves survival outcomes for patients with metastatic kidney cancer.

## Contribution

Demonstrates that cytoreductive nephrectomy is an independent prognostic factor for better survival in metastatic renal cell carcinoma.

## Key findings

- Patients who underwent cytoreductive nephrectomy had a median cancer-specific survival of 32 months versus 14 months without it.
- Cytoreductive nephrectomy was independently associated with improved progression-free and cancer-specific survival.
- The study confirms the clinical benefit of cytoreductive nephrectomy in real-world metastatic renal cell carcinoma management.

## Abstract

In this study, we aimed to determine the utility of cytoreductive nephrectomy (CN) in real-world clinical practice and investigate whether CN contributes to improved oncological outcomes in patients with metastatic renal cell carcinoma (mRCC). This retrospective multicenter cohort study enrolled patients with mRCC who received systemic therapy at six institutions between May 2005 and May 2023. The patients were divided into those who did not undergo CN (Group I) and those who underwent CN (Group II). The primary endpoints were oncological outcomes, including cancer-specific survival (CSS) and progression-free survival (PFS). Altogether, 137 patients with mRCC were included in this study. The median CSS was 14 months in Group I and 32 months in Group II (p < 0.001). Additionally, the median PFS in Groups I and II was 5 and 13 months, respectively (p = 0.006). A multivariate analysis showed that CN was an independent prognostic factor for CSS and PFS. Hence, CN is a potential treatment modality that can improve oncological outcomes in patients with mRCC.